Panolos Bioscience
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent (NCT06075849) | Panolos Bioscience | 2023-10-25 |
Track Panolos Bioscience automatically
Every clearance here is in the API, with alerts when new ones post.